Related Experiment Video

Updated: May 25, 2025

Purification of Ubiquitinated p53 Proteins from Mammalian Cells
10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.0K

Targeting the PARylation-Dependent Ubiquitination Signaling Pathway for Cancer Therapies

Daoyuan Huang1, Jingchao Wang1, Li Chen1

  • 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

Biomolecules
|February 26, 2025
PubMed

Insights

Poly(ADP-ribosyl)ation (PARylation) is a crucial protein modification regulating DNA repair and gene expression. The PAR-dependent ubiquitination (PARdU) pathway, involving RNF146 and tankyrase, is vital for cancer therapy.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Cancer Biology

Background:

  • Poly(ADP-ribosyl)ation (PARylation) is a dynamic post-translational modification (PTM) essential for cellular processes.
  • PAR-dependent ubiquitination (PARdU) involves RNF146 and tankyrase, regulating protein degradation.
  • The PARdU pathway is implicated in tumorigenesis, immune responses, and cell death.

Purpose of the Study:

  • To review the molecular mechanisms of the PARdU pathway.
  • To highlight the biological functions and therapeutic potential of PARdU in cancer.
  • To discuss strategies targeting PARdU for precision oncology.

Main Methods:

  • Literature review of PARylation and PARdU pathways.
  • Analysis of RNF146-tankyrase interactions and substrate specificity.
  • Exploration of therapeutic strategies including inhibitors and immune modulation.

Main Results:

  • Detailed elucidation of PARdU pathway mechanisms, including enzyme interactions and regulation.
  • Demonstration of PARdU's role in DNA repair, signaling, and metabolism.
  • Identification of PARdU as a key regulator in cancer development.

Conclusions:

  • The PARdU pathway is a critical regulator with significant therapeutic potential in oncology.
  • Targeting tankyrase and RNF146 offers promising avenues for cancer treatment.
  • PARdU represents a transformative therapeutic target for various human cancers.
Keywords:
PARylation ubiquitinationRNF146tankyrase

More Related Videos

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

5.5K
Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

2.4K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
6.8K
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
7.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K